Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DU3GQ9
|
|||
| Drug Name |
TP-271
|
|||
| Synonyms |
UNII-Y6IUM7395Q; Y6IUM7395Q; 1207284-17-0; (S)-N-((5aR,6aS,7S,10aS)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,8,10a,11-tetrahydroxy-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl)-1-methylpyrrolidine-2-carboxamide; (2S)-N-((5aR,6aS,7S,10aR)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,10,10a,12-tetrahydroxy-8,11-dioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl)-1-methylpyrrolidine-2-carboxamide; (2S)-N-[(5aR,6aS,7S,10aR)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,10,10a,12-tetrahydroxy-8,11-dioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-1-methylpyrrolidine-2-carboxamide; CHEMBL2057236; SCHEMBL13397803; GTPL11013; TP271; DB15040
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pneumonia [ICD-11: CA40] | Phase 1 | [1] | |
| Respiratory tract infection [ICD-11: CA45; ICD-10: J13, J15] | Phase 1 | [2] | ||
| Company |
Tetraphase Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H31FN4O8
|
|||
| Canonical SMILES |
CN1CCCC1C(=O)NC2=CC(=C3CC4CC5C(C(=O)C(=C(C5(C(=O)C4=C(C3=C2O)O)O)O)C(=O)N)N(C)C)F
|
|||
| InChI |
1S/C27H31FN4O8/c1-31(2)19-12-8-10-7-11-13(28)9-14(30-26(39)15-5-4-6-32(15)3)20(33)17(11)21(34)16(10)23(36)27(12,40)24(37)18(22(19)35)25(29)38/h9-10,12,15,19,33-34,37,40H,4-8H2,1-3H3,(H2,29,38)(H,30,39)/t10-,12-,15-,19-,27-/m0/s1
|
|||
| InChIKey |
VIWUYPVRNWIKLS-HMFHYXQTSA-N
|
|||
| CAS Number |
CAS 1207284-17-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial 30S ribosomal RNA (Bact 30S rRNA) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02724085) A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03234738) A Phase 1 Safety and PK Study of IV TP-271. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.